Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...

Its biosimilar of Roche’s cancer and autoimmune disease drug MabThera (rituximab) is already on sale in Germany under the brand name Truxima.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Review the current Roche Holding AG (ROG:XSWX) dividend yield and history to decide if ROG is the best investment for you.